Mirati Therapeutics Stock News

Mirati Therapeutics, Inc. (NASDAQ:MRTX) EVP Jamie Christensen sold 1,201 shares of Mirati Therapeutics stock in a transaction that occurred on Monday, December 6th. The stock was sold at an average price of $130.79, for a total value of $157,078.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can []

Molecular Templates (NASDAQ:MTEM) and Mirati Therapeutics (NASDAQ:MRTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability. Volatility & Risk Molecular Templates has a beta of 1.11, suggesting that its share price is [] The post Analyzing Mirati Therapeutics (NASDAQ:MRTX) & Molecular Templates (NASDAQ:MTEM) appeared first on ETF Daily News .

Mirati Therapeutics, Inc. (NASDAQ:MRTX) insider Charles M. Baum sold 47,204 shares of the companys stock in a transaction that occurred on Friday, December 3rd. The shares were sold at an average price of $133.20, for a total value of $6,287,572.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which []

Mirati Therapeutics, Inc. (NASDAQ:MRTX) insider Charles M. Baum sold 47,204 shares of Mirati Therapeutics stock in a transaction that occurred on Friday, December 3rd. The stock was sold at an average price of $133.20, for a total value of $6,287,572.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can []

In last trading session, Mirati Therapeutics Inc. (NASDAQ:MRTX) saw 0.64 million shares changing hands with its beta currently measuring 1.24. Companys recent per share price level of $132.35 trading at -$4.71 or -3.44% at ring of the bell on the day assigns it a market valuation of $7.23B. That closing price of MRTXs stock is Analysts Say That Mirati Therapeutics Inc. (NASDAQ:MRTX) Is Likely To Make It To $300.00 In 12 Months Read More »

Mirati Therapeutics, Inc. (NASDAQ:MRTX)s share price gapped up prior to trading on Friday . The stock had previously closed at $132.04, but opened at $140.74. Mirati Therapeutics shares last traded at $135.50, with a volume of 713 shares traded. Several equities research analysts have commented on the company. JPMorgan Chase & Co. lowered their price []

Mirati Therapeutics (MRTX) partners Verastem Oncology (VSTM) to evaluate adagrasib in combination with VS-6766 in KRASG12C-mutant non-small cell lung cancer.

(RTTNews) - Mirati Therapeutics Inc. (MRTX) and Verastem Oncology (VSTM) have collaborated to evaluate the combination of Mirati''s investigational KRASG12C inhibitor adagrasib with Verastem Oncology''s investigational RAF/MEK inhibitor VS-6766 in KRASG12C-mutant non-small cell lung cancer (NSCLC), the companies said in a statement.

Mirati Therapeutics, Inc. (Nasdaq:MRTX), a clinical-stage targeted oncology company and Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company c

Mirati Therapeutics, Inc. (NASDAQ:MRTX)s stock price shot up 4.2% during mid-day trading on Friday . The stock traded as high as $143.30 and last traded at $143.25. 540 shares were traded during mid-day trading, a decline of 100% from the average session volume of 492,921 shares. The stock had previously closed at $137.45. A number []

Mirati (MRTX) submits an investigational new drug application to the FDA for MRTX1719 for the treatment of methylthioadenosine phosphoylase-deleted cancers.

Mirati (MRTX) submits an investigational new drug application to the FDA for MRTX1719 for the treatment of methylthioadenosine phosphoylase-deleted cancers.

The CHMP gives a positive opinion on, and recommends approval to Amgen's (AMGN) KRAS inhibitor, Lumykras for the treatment of advanced non-small-cell lung cancer.

Arcutis Biotherapeutics (NASDAQ:ARQT) and Mirati Therapeutics (NASDAQ:MRTX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership. Valuation and Earnings This table compares Arcutis Biotherapeutics and Mirati Therapeutics top-line revenue, earnings per share []